Related Experiment Video

Updated: Mar 29, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression

Chiun Hsu1, Liang-In Lin2, Yu-Che Cheng2

  • 1Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 26, 2015
PubMed
Abstract

Insights

Suppressing cyclin E1 (cell cycle protein) can overcome sorafenib resistance in liver cancer. Combining sorafenib with CDK inhibitors enhances its antitumor effects, offering a potential new therapy for hepatocellular carcinoma.

Area of Science:

  • Molecular oncology
  • Hepatocellular carcinoma research
  • Cancer therapy development

Background:

  • Sorafenib is a standard treatment for hepatocellular carcinoma (HCC).
  • Resistance to sorafenib remains a significant clinical challenge in HCC treatment.
  • The role of cell cycle regulators like cyclin E1 in sorafenib resistance is not fully understood.

Purpose of the Study:

  • To investigate the impact of cyclin E1 suppression on sorafenib's effectiveness against HCC cells.
  • To explore the therapeutic potential of combining sorafenib with cyclin-dependent kinase (CDK) inhibitors.

Main Methods:

  • Tested sorafenib efficacy in sensitive and resistant HCC cell lines with and without cyclin E1 modulation.
  • Utilized Western blotting to analyze signaling pathways and protein expression.
  • Evaluated combination therapy (sorafenib + flavopiridol) in vitro and in vivo xenograft models.

Main Results:

  • Cyclin E1 suppression reversed sorafenib resistance in HCC cells, enhancing apoptosis and growth inhibition.
  • Overexpression of cyclin E1 increased resistance to sorafenib.
  • Combination therapy with sorafenib and flavopiridol (a pan-CDK inhibitor) showed enhanced antitumor effects, partly mediated by Mcl-1 suppression.

Conclusions:

  • Cyclin E1 suppression may serve as a predictive biomarker for sorafenib response in HCC.
  • Combining sorafenib with CDK inhibitors presents a promising strategy to improve treatment outcomes in HCC.
  • Targeting cyclin E1 and CDK pathways could overcome sorafenib resistance in liver cancer.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K
SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

7.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.1K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
137.1K